Carl G Osborne

US Patent:

20100009981, Jan 14, 2010

Filed:

Jul 10, 2009

Appl. No.:

12/501202

Inventors:

Iain W. Duncan - Seattle WA, US
Edward A. Kesicki - Bothell WA, US
Carl G. Osborne - Jacksonville FL, US
William D. Schwieterman - Mobile AL, US
Irina Jacobson - Sammamish WA, US

Assignee:

Neumedics - Seattle WA

International Classification:

A61K 31/536
A61K 31/423

US Classification:

5142295, 514375

Abstract:

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10.

US Patent:

20130123217, May 16, 2013

Filed:

Dec 13, 2012

Appl. No.:

13/714052

Inventors:

Edward A. Kesicki - Bothwell WA, US
Carl G. Osborne - Jacksonville FL, US
William D. Schwieterman - Mobile AL, US
Irina Jacobson - Sammamish WA, US

Assignee:

NEUMEDICS - Seattle WA

International Classification:

A61K 31/65
A61K 45/06
C07D 498/10
C07C 233/58
C07D 265/34
C07D 263/52

US Classification:

514154, 544 99, 514152, 548221, 548216, 552200, 435 32, 435 15, 435 29

Abstract:

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10.

US Patent:

20170144979, May 25, 2017

Filed:

Feb 8, 2017

Appl. No.:

15/427235

Inventors:

- Seattle WA, US
Edward A. Kesicki - Bothell WA, US
Carl G. Osborne - Lovettsville VA, US
William D. Schwieterman - Mobile AL, US
Irina Jacobson - Sammamish WA, US

International Classification:

C07D 265/34
C07D 263/52

Abstract:

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions and

US Patent:

20160009668, Jan 14, 2016

Filed:

Sep 22, 2015

Appl. No.:

14/860803

Inventors:

- Seattle WA, US
Edward A. Kesicki - Bothell WA, US
Carl G. Osborne - Lovettsville VA, US
William D. Schwieterman - Mobile AL, US
Irina Jacobson - Sammamish WA, US

International Classification:

C07D 265/34
C07D 263/52

Abstract:

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10.